Look for the Continuation Decision next week

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 1669
Joined: Fri Jul 20, 2018 5:13 pm

Look for the Continuation Decision next week

Post by biopearl123 » Wed Jul 25, 2018 3:36 am

Hoping for some important news delivered during the next quarterly update on next Tuesday. While Geron can't control the timing of an FDA change in drug status (e.g. AA), I believe they would time the conference call to coincide with a Janssen decision. It will have been three months since the MF trial completed and also even more time since the "new" 25 MDS patients could be evaluated for 8 week TI (at a minimum). So clearly Janssen has what it needs to decide to continue or not. This would be an obvious time to say so. bp

j6proulx
Posts: 23
Joined: Mon Jun 25, 2018 10:20 pm

Re: Look for the Continuation Decision next week

Post by j6proulx » Wed Jul 25, 2018 6:54 am

I share your opinion that I expect the continuation decision in the near future. This week will be three full months since the primary analysis began for IMbark. We know that Janssen has to complete the primary analysis and also submit a clinical development plan for Geron's consideration of whether to opt in.

I also suspect Janssen is pursuing accelerated approval for imetelstat in MF based on the IMbark primary analsys and results of the recently completed Mayo study. To get a sense of what's involved in requesting NDA approval, I researched clinical study reports submitted for approved drugs. The FDA recently instituted a pilot program for data transparency with drug approvals. Janssen was the first company to participate, with its Erleada being the first drug approval in the pilot program. Erleada's clinical trial protocol, clinical study report, approval letter, FDA correspondence, etc., are all available on the FDA's website: https://www.accessdata.fda.gov/drugsatf ... 51_toc.cfm . I see this as a window into the details and scope of information associated with FDA approvals.

I suspect the three months from April 26 start of the primary analysis is sufficient time to complete this work. If Janssen has been working on the clinical development plan concurrently, the company would be in position to make its continuation decision very soon. I am anxious to learn what additional indications are identified and I hope this information is made public. Best wishes to all.

cheng_ho
Posts: 202
Joined: Sun Apr 03, 2016 11:27 pm

Re: Look for the Continuation Decision next week

Post by cheng_ho » Wed Aug 15, 2018 9:46 pm

I looked and I looked but I couldn't find the CD ;)

...is JNJ actually going to sit on this until Sept 28th?

biopearl123
Posts: 1669
Joined: Fri Jul 20, 2018 5:13 pm

Re: Look for the Continuation Decision next week

Post by biopearl123 » Fri Aug 17, 2018 1:43 am

Cheng, Very funny, very funny. I looked too and couldn't find it, must just be looking in the wrong place (or the wrong time). bp

Post Reply